Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06268860 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
NCT06268860 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 240 participants.
The verdict
NCT06268860, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
Interventions
- DRUG Rocatinlimab vial injection
- COMBINATION_PRODUCT Rocatinlimab prefilled syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06268860
The ClinicalTrials.gov registry entry for NCT06268860 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rocatinlimab vial injection is the first listed.
NCT06268860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06268860 about?
NCT06268860 is a clinical study titled "A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants". The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
What is the current status of trial NCT06268860?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-02-15. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT06268860?
The interventions under investigation include: Rocatinlimab vial injection (DRUG), Rocatinlimab prefilled syringe (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06268860?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.